Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death and the search for a resolutive therapy is still a challenge. Since KRAS is commonly mutated in PDAC and is one of the main drivers of PDAC progression, its inhibition should be a key strategy for treatment, especiall...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Francesca Ricciardiello, Laura Bergamaschi, Humberto De Vitto, Yang Gang, Taiping Zhang, Roberta Palorini, Ferdinando Chiaradonna
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-02-01
Colecção:	Cells
Assuntos:	PDAC hexosamine biosynthetic pathway glycosylations KRAS KRAS inhibitors cancer treatment
Acesso em linha:	https://www.mdpi.com/2073-4409/10/2/431
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!